Kari Lislerud
Position: Research associate, Msc
Phone: +47 22 78 23 19


1994-1996       Further education for biomedical laboratory scientists at Høgskolen i Oslo

1986-1988       NKI- 11\2 y study- management within the health sector

1978                State school for Biomedical laboratory scientists, Riskhospitalet. Authorized Biomedical laboratory scientist

1992- 2003      Various courses: Work environment Chemistry –University of Oslo (UIO), General biochemistry-UIO.


Research interests/projects:

  • Detection and culture of antigen-specific T cells
  • T-cell cloning
  • T-cell characterisation


Work experience

1995-present               Research assistant at The Radium Hospital- Dept. Of Cellular Therapy. Currently working on a project with a cancer vaccine start-up company.

1989 - 1995                 Rikshospitalet- Institute for transplantation immunology.

1985-1989                   Rikshospitalet- Blood bank and immunohaematology laboratory, later Red Cross and Rikshopsitalet Blood Centre.

1983-1985                   Rikshospitalet-Institute of general and rheumatoid immunology.

1981-1983                   Several clinical laboratories;  Glittre Sanatorium and Rikshospitalet, Paediatric clinic and medcine.

1978-1981                   Rikshospitalet- Pathology Dept. Section for autopsi and biopsi (State Institute for Radiation Protection).



Author network for Kari Lislerud by COREMINE medical

Publications 2016

Kyte JA, Gaudernack G, Faane A, Lislerud K, Inderberg EM, Brunsvig P, Aamdal S, Kvalheim G, Wälchli S, Pule M (2016)
T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy
Oncoimmunology, 5 (12), e1249090
PubMed 28123886

Publications 2012

Inderberg-Suso EM, Trachsel S, Lislerud K, Rasmussen AM, Gaudernack G (2012)
Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001
Oncoimmunology, 1 (5), 670-686
PubMed 22934259

Publications 2010

Rasmussen AM, Borelli G, Hoel HJ, Lislerud K, Gaudernack G, Kvalheim G, Aarvak T (2010)
Ex vivo expansion protocol for human tumor specific T cells for adoptive T cell therapy
J Immunol Methods, 355 (1-2), 52-60
PubMed 20171968

Publications 2009

Kyte JA, Trachsel S, Risberg B, thor Straten P, Lislerud K, Gaudernack G (2009)
Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination
Cancer Immunol Immunother, 58 (10), 1609-26
PubMed 19221745

Publications 2006

Kyte JA, Kvalheim G, Lislerud K, thor Straten P, Dueland S, Aamdal S, Gaudernack G (2006)
T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells
Cancer Immunol Immunother, 56 (5), 659-75
PubMed 16947019

Kyte JA, Mu L, Aamdal S, Kvalheim G, Dueland S, Hauser M, Gullestad HP, Ryder T, Lislerud K, Hammerstad H, Gaudernack G (2006)
Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA
Cancer Gene Ther, 13 (10), 905-18
PubMed 16710345

Publications 2001

Saeterdal I, Bjørheim J, Lislerud K, Gjertsen MK, Bukholm IK, Olsen OC, Nesland JM, Eriksen JA, Møller M, Lindblom A, Gaudernack G (2001)
Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer
Proc Natl Acad Sci U S A, 98 (23), 13255-60
PubMed 11687624